TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2136871
Drug: Amitriptyline (100-225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (100-225 mg)
Study: 6146371
Drug: Anxiolytic medication
Normalized name: ANXIOLYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anxiolytic medication
Study: 69290
Drug: Diamorphine and
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamorphine and Morphine
Study: 29658257
Drug: Ningmitai Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ningmitai Capsules (NMT)
Study: 29658257
Drug: Ningmitai Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ningmitai Capsules + Doxycycline hydrochloride (NMT+DH)
Study: 24655693
Drug: 6-week clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-week clopidogrel therapy
Study: 24655693
Drug: 6-month clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month clopidogrel therapy
Study: 21288215
Drug: Propofol 1.5-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.5-2 mg/kg
Study: 19635155
Drug: Postoperative IABP
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative IABP therapy
Study: 12890209
Drug: Itraconazole pulse
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole pulse therapy for 2 months and amorolfine 5% solution nail lacquer for 6 months
Study: 12890209
Drug: Itraconazole monotherapy
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole monotherapy (three pulses)
Study: 10225576
Drug: Cefotaxime 1
Normalized name: cefotaxime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 1 g
Study: 2228842
Drug: Five day
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five day oral course of co-amoxyclav (amoxycillin plus clavulanic acid)
Study: 31267367
Drug: JNJ-6379 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-6379 (25 to 600 mg)
Study: 31267367
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg JNJ-6379 twice daily for 2 days, followed by 100 mg JNJ-6379 daily for 10 days
Study: 28377156
Drug: Milk protein
Normalized name: Milk protein
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk protein supplementation (2 × 15 g, twice daily) during 24 weeks of resistance-type exercise training
Study: 18851885
Drug: One of
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One of nine treatments for depression
Study: 15198760
Drug: Povidone-iodine gel
Normalized name: povidone-iodine gel 10 % Medicated Pad
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine gel (20 cc) at the vaginal apex
Study: 15198760
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no povidone-iodine gel)
Study: 7995011
Drug: Nitroglycerin (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (intravenous infusion during the first 24 hours, then 10 mg/day transdermal)
Study: 7995011
Drug: Lisinopril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (5 then 10 mg/day)
Study: 23828228
Drug: Decapeptyl (n=30)
Normalized name: N-Vanillylnonamide
DrugBank: Nonivamide (DB11324)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decapeptyl (n=30) every 4 weeks for 4 doses
Study: 15456517
Drug: Multispecies probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multispecies probiotic preparation (Ecologic 641) administered twice daily through a nasojejunal tube for 28 days or until discharge.
Study: 15456517
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered twice daily through a nasojejunal tube for 28 days or until discharge.
Study: 15456517
Drug: Multispecies probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multispecies probiotic preparation (Ecologic 641)
Study: 10786739
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia with 8 mg of 0.5% hyperbaric bupivacaine
Study: 10786739
Drug: Combined sciatic‐femoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined sciatic‐femoral nerve block with 25 ml of mepivacaine 20 mg ml(‐1)
Study: 3527523
Drug: Porcine lente
Normalized name: INSULIN,LENTE,BEEF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porcine lente insulin
Study: 18605455
Drug: routine rinsing
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: routine rinsing treatment (negative group)
Study: 12492913
Drug: RCT-Ps covering
Normalized name: Canker Cover
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCT-Ps covering periodontal surgery and gingivitis/plaque treatment or prevention
Study: 28434871
Drug: Volitional helpsheet
Normalized name: ZINC OXIDE 132 mg in 1 mL TOPICAL LOTION [Volition Prismatic Luminizing Shield]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volitional helpsheet (VHS) plus usual treatment
Study: 24442244
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy plus autologous stem cell transplant (ASCT)
Study: 24442244
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy plus ASCT
Study: 19335882
Drug: Topical wound
Normalized name: Solox Gel Silver Antimicrobial Topical Wound Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical wound treatment
Study: 21476613
Drug: Memantine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (10 mg twice daily)
Study: 10818061
Drug: Nifedipine once
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine once daily
Study: 11408386
Drug: Co-amilozide (hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amilozide (hydrochlorothiazide 25 mg, amiloride 2.5 mg)
Study: 8231842
Drug: LDL3 cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL3 cholesterol level < 1.8 mmol/L
Study: 29737068
Drug: Low concentration
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low concentration contrast agent combined double low dose (80 kV, 15 mL, 320 mg I/mL)
Study: 29737068
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (120 kV, 50 mL, 370 mg I/mL)
Study: 21861080
Drug: Pre-treatment aneurysm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment aneurysm re-rupture
Study: 16965889
Drug: GOES treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GOES treatment
Study: 10885864
Drug: Memantine 10
Normalized name: Memantine 10mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine 10 mg per day
Study: 8625152
Drug: Combined cisplatin-based
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined cisplatin-based chemotherapy and radiotherapy
Study: 8625152
Drug: Combined noncisplatin-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined noncisplatin-based chemotherapy and radiotherapy
Study: 14668568
Drug: Twice-daily lisinopril
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily lisinopril (5-20 mg/d)
Study: 14668568
Drug: Once-daily lisinopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily lisinopril (5-20 mg/d)
Study: 11181127
Drug: 6-month short-course
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month short-course therapy for tuberculosis including rifampin
Study: 11181127
Drug: 6-month short-course
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month short-course therapy for tuberculosis without HIV infection
Study: 9833167
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (antihypertensive drug)
Study: 9833167
Drug: Restrictive antihypertensive
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive antihypertensive therapy (control)
Study: 8058004
Drug: Escherichia coli
Normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escherichia coli L‐asparaginase
Study: 8058004
Drug: Erwinia chrysanthemi
Normalized name: Erwinia chrysanthemi
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erwinia chrysanthemi L‐asparaginase
Study: 8058004
Drug: Both E.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both E. coli and Erwinia L‐asparaginase
Study: 4004503
Drug: Drug counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug counseling
Study: 4004503
Drug: Helping Alliance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helping Alliance Questionnaire (early-in-treatment measure)
Study: 4004503
Drug: Purity of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purity of therapy techniques
Study: 21565903
Drug: Empirical antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical antifungal therapy
Study: 30010931
Drug: Pre-emptive antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-emptive antifungal therapy
Study: 22545821
Drug: Narrative Enhancement/Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative Enhancement/Cognitive Therapy (NECT)
Study: 17490978
Drug: Fish-oil (FO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil (FO) supplementation (0.5 g DHA and 0.15 g EPA)
Study: 10829315
Drug: Neoadjuvant radiochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant radiochemotherapy in combination with RO-resection
Study: 8785149
Drug: ondansetron 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 0.06 mg kg‐1 i.v.
Study: 8785149
Drug: prochlorperazine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: prochlorperazine 0.2 mg kg‐1 i.m.
Study: 8785149
Drug: prochlorperazine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: prochlorperazine 0.1 mg kg‐1 i.v.
Study: 3886141
Drug: Doxepin hydrochloride
Normalized name: Doxepin Hydrochloride
DrugBank: Doxepin (DB01142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxepin hydrochloride (50 mg during the first week, and 100 mg thereafter, at bedtime)
Study: 3886141
Drug: Cimetidine (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1,200 mg/day in four divided doses)
Study: 30318393
Drug: saline +
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline + NE (5 μg/min)
Study: 30318393
Drug: phentolamine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: phentolamine + NE (2.5 mg/min)
Study: 28280053
Drug: Copeptin levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copeptin levels measured in patients with eGFR 60-89 mL/min/1.73 m2
Study: 24853591
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA) - Hyalgan intra-articular injection, Sodium hyaluronate 10 mg/ml, 2 ml injection
Study: 24853591
Drug: Tenoxicam (TX)
DrugBank: Tenoxicam (DB00469)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam (TX) - Tilcotil flacon, 20 mg tenoxicam/ml
Study: 24853591
Drug: Betamethasone (CS)
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone (CS) - Diprospan flacon, 7.0 mg betamethasone/1 ml
Study: 24853591
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - Saline solution injected intra-articularly
Study: 11495396
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (placebo stimulation)
Study: 11495396
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (active and sham treatment)
Study: 7894539
Drug: Comparative drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparative drugs (benzodiazepines)
Study: 3310750
Drug: Intravenous terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous terbutaline (6 micrograms/kg, two times at an hour interval)
Study: 3310750
Drug: Inhaled terbutaline
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled terbutaline (0.1 mg/kg, two times)
Study: 18036807
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine (NAC) 1800 mg daily for 4 months
Study: 8845325
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of medroxyprogesterone acetate (1000 mg p.o. q.d.s. for 48 h)
Study: 8845325
Drug: Oral maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral maintenance dose of 1000 mg daily
Study: 8845325
Drug: Oral maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral maintenance dose of 500 mg daily
Study: 495086
Drug: Flunarizine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (20 mg t.i.d. for three days) in Study I (50 patients)
Study: 495086
Drug: Flunarizine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (20 mg t.i.d. for two months) in Study II (31 patients)
Study: 495086
Drug: Flunarizine (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (weekly decreasing doses for three months) in Study III (9 patients with vertigo of recent origin)
Study: 495086
Drug: Placebo (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (weekly decreasing doses for three months) in Study III (18 patients with vertigo of recent origin)
Study: 30427232
Drug: Sweet solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sweet solution
Study: 28802290
Drug: Encover® 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encover® 400 ml/day for 8 weeks
Study: 23968123
Drug: Dopamine partial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine partial Agonist, Aripiprazole
Study: 15522378
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg triamcinolone acetonide sub‐Tenon's capsule injection
Study: 11504661
Drug: Intermittent parathyroid
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent parathyroid hormone (PTH) administration
Study: 9438594
Drug: Weekly 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly 5-fluorouracil chemotherapy
Study: 26178500
Drug: Propofol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1 mg/kg for induction, maintenance 0.5 mg/kg/h)
Study: 26178500
Drug: Right beauty
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right beauty pyrimidine (1 mg/kg/h for 20 min, maintenance 0.3-0.7 mg/kg/h)
Study: 21135266
Drug: Daily sunscreen
Normalized name: ZINC OXIDE 220 mg in 1 mL TOPICAL CREAM [SPF 30 Daily Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sunscreen application
Study: 19860981
Drug: Biological specimen
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological specimen collection (blood and urine)
Study: 1383520
Drug: Oral fluid
Normalized name: cascara sagrada ORAL FLUID EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluid only
Study: 3890764
Drug: Bedtime insulin
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime insulin injections
Study: 3890764
Drug: Teatime insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Teatime insulin injections
Study: 23838604
Drug: ACE inhibitor-associated
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor-associated angioedema
Study: 23838604
Drug: G allele
Approvals — FDA: no, EMA: no, PMDA: no
Description: G allele of rs2724635 in ETV6
Study: 12675646
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart with intensified basal NPH insulin supplementation
Study: 12675646
Drug: Human regular
Normalized name: Human regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human regular insulin with standard basal NPH insulin
Study: 11123453
Drug: Psoralen-ultraviolet A
Normalized name: Psoralen
DrugBank: Psoralen (DB18665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psoralen-ultraviolet A (PUVA) therapy
Study: 11123453
Drug: Psoralen-ultraviolet B
Normalized name: Psoralen
DrugBank: Psoralen (DB18665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psoralen-ultraviolet B (PUVB) therapy
Study: 9177984
Drug: Ambroxol treatment
Normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol treatment (group A)
Study: 1545249
Drug: AT877 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT877 (30 mg, intravenous injection over 30 minutes, three times a day for 14 days)
Study: 1545249
Drug: Placebo (saline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline, intravenous injection over 30 minutes, three times a day for 14 days)
Study: 28634654
Drug: guselkumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab treatment
Study: 26450000
Drug: Pump design
Normalized name: Designer Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pump design modifications and protocol-driven change in antiplatelet therapy
Study: 26450000
Drug: Aspirin ≤81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin ≤81 mg and atrial fibrillation
Study: 26450000
Drug: Mean arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean arterial pressure >90 mm Hg, aspirin ≤81 mg, and international normalized ratio >3.0
Study: 20465357
Drug: Intravenous cortisol
Normalized name: Corticool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cortisol infusion before retrieval testing
Study: 19552867
Drug: Duloxetine 60‐120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60‐120 mg once daily
Study: 17377086
Drug: Dexamethasone 4
Normalized name: dexamethasone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 4 mg + Ondansetron 4 mg (Group D4/O4)
Study: 17377086
Drug: Dexamethasone 4
Normalized name: dexamethasone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 4 mg + Ondansetron 2 mg (Group D4/O2)
Study: 17377086
Drug: Dexamethasone 2
Normalized name: dexamethasone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 2 mg + Ondansetron 4 mg (Group D2/O4)
Study: 17377086
Drug: Dexamethasone 2
Normalized name: dexamethasone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 2 mg + Ondansetron 2 mg (Group D2/O2)
Study: 17377086
Drug: Dexamethasone 2
Normalized name: dexamethasone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 2 mg (Groups D2/O4 and D2/O2)
Study: 15000732
Drug: Benzathine penicillin
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathine penicillin (1.2 million units as a single dose)
Study: 15000732
Drug: Metronidazole (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (600 mg every 6 h for 10 days)
Study: 9665189
Drug: High-dose AraC
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose AraC (3.0 g/m2 for patients younger than 60 years; 1.0 g/m2 for older patients)
Study: 9665189
Drug: Intermediate-dose AraC
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-dose AraC (1.0 g/m2 for patients younger than 60 years; 0.5 g/m2 for older patients)
Study: 9665189
Drug: High-dose AraC
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose AraC in refractory AML subgroup
Study: 9665189
Drug: Intermediate-dose AraC
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-dose AraC in older patients
Study: 709793
Drug: Powder administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Powder administration of beclomethasone dipropionate (100 micrograms, 4 doses)
Study: 709793
Drug: Aerosol administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosol administration of beclomethasone dipropionate (100 micrograms, 4 doses)
Study: 24183218
Drug: Topical minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minoxidil 5%
Study: 31957152
Drug: Oral finasteride
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral finasteride 1 mg daily
Study: 31957152
Drug: Control lotion
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control lotion (1 mL/d)
Study: 23385271
Drug: Ramipril 10
Normalized name: ramipril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 10 mg/d for 24 weeks
Study: 21115010
Drug: Aspirin/NSAID use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin/NSAID use after blood collection
Study: 14986556
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg intranasal butorphanol (single dose)
Study: 14986556
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg intranasal butorphanol (single dose)
Study: 14986556
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg intranasal butorphanol (multiple doses every six hours for seven doses)
Study: 14986556
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg intranasal butorphanol (multiple doses every six hours for seven doses)
Study: 14986556
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg and 2 mg intranasal butorphanol
Study: 14986556
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg vs 1 mg intranasal butorphanol (single dose)
Study: 7870219
Drug: First-line chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line chemotherapy with cisplatin
Study: 7870219
Drug: Second/third-line chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second/third-line chemotherapy with cisplatin